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In many disease genes, a substantial fraction of all rare variants detected cannot yet be used for genetic counselling
because of uncertainty about their association with disease. One approach to the characterization of these unclassiﬁed
variants is the analysis of patterns of cosegregation with disease in affected carrier families. Petersen et al. previously
provided a simplistic Bayesian method for evaluation of causality of such sequence variants. In the present report,
we propose a more general method based on the full pedigree likelihood, and we show that the use of this method
can provide more accurate and informative assessment of causality than could the previous method. We further
show that it is important that the pedigree information be as complete as possible and that the distinction be made
between unaffected individuals and those of unknown phenotype.
The identiﬁcation of speciﬁc genes involved in a number
of common diseases has brought genetic testing into clin-
ical practice. For many of these genes, the sequence var-
iants that have been identiﬁed include known deleterious
mutations (often protein truncating), recognized poly-
morphisms, and rare variants (usually missense chang-
es). The last category poses problems for genetic coun-
selling, since tested individuals and their families are
given an uninformative result unless sufﬁcient evidence
is available that a given missense change is deleterious.
In the case of BRCA1 and BRCA2, these so-called “un-
classiﬁed variants” account for approximately one-half
of all variants (other than common polymorphisms) de-
tected (see, e.g., Frank et al. 2002) and were present in
13% of the women tested in the study by Frank et al.
(2002).
Various types of evidence may help to classify such
variants as deleterious or neutral with respect to the dis-
ease of interest; these include the nature and position of
the amino acid substitution, the degree of conservation
among species, and the results of functional assays. How-
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ever, the evidence most relevant to the genetic-counselling
problem comes from two main sources. First, there may
be epidemiological data on the frequency of the variants
in families with different personal and family history of
disease as compared with their frequency in the general
population. The difﬁculty is that often the variants of
interest are quite rare, precluding assessment in even large
case-control series. Second—and more readily available
in practice—is evidence obtained through examination of
the extent of cosegregation of the variant with disease in
families in which a given sequence variant has been
identiﬁed.
The general design is that in which a single individual
from a family (usually affected) has been tested and
found to harbor a sequence variant of unknown signif-
icance in a particular gene. Subsequently, additional fam-
ily members are tested for the speciﬁc variant. The goal
is to evaluate the evidence for the causality associated
with the speciﬁc variant with reference to the disease of
interest. Typically, this involves testing the hypothesis
that the variant confers some speciﬁed risk (e.g., that
conferred by known deleterious mutations) against the
hypothesis of complete neutrality (i.e., wherein the var-
iant is not associated with any increased risk of the dis-
ease). In principle, one could consider a more general
model in which the variant confers some intermediate
risk, but, except for relatively common founder variants
such as BRCA1 185delAG, it is rarely possible to ac-
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cumulate enough data to estimate the average risks as-
sociated with a speciﬁc variant.
To address this problem, Petersen et al. (1998) de-
veloped a method for calculating what they termed
“Bayes factors of causality,” which are based on the
degree of relationship to the proband and genotype/car-
rier status at the presumed causal variant of each tested
relative. In situations in which the penetrance/relative
risk of the causal allele is unknown, Petersen et al. (1998)
proposed the use of a Bayesian approach, with an as-
sumed prior distribution for the penetrances conferred
by the variant in question. Although this approach can
be applied to a number of practical problems, their spe-
ciﬁc formulation suffers from some limitations. Most
restrictive is that it does not easily allow for different
risks (absolute or relative) for individuals as a function
of, for example, their age and sex. Furthermore, tested
unaffected individuals are not included in their method.
For high-risk alleles, the respective genotypes of older
unaffected individuals may contribute information on
causality. Last, there is some information to be gained
from the phenotypes of individuals who have not been
genotyped but whose genotype may be partially inferred
from the genotypes of their close relatives. Petersen et
al. (1998) provided a simple S-plus program to imple-
ment their method in the case of a rare disease allele.
As noted by Petersen et al. (1998), this simpliﬁcation
also ignores the dependence between multiple tested in-
dividuals in the same pedigree. To overcome these lim-
itations, we propose here a more general formulation
that is easily implemented in existing genetic analysis
programs and that reduces to the method of Petersen et
al. (1998) in those cases in which the latter can be used.
We note that the relevant likelihood ratio (or Bayes
factor) is of the form
( )L VFP,V ,Cp 1p
Bp .( )L VFP,V ,Cp 0p
Here, P is the vector of disease phenotypes within the
family, V is the vector of the variant genotypes, and Vp
is the variant genotype of the proband. Following Pe-
tersen et al. (1998), when the variant is diseaseCp 1
causing, and when the variant is neutral. By “cau-Cp 0
sality,” we mean that a given variant has a penetrance
or relative risk of disease (perhaps age and/or sex spe-
ciﬁc) equal to that of proven deleterious mutations (or
some other prespeciﬁed value). Since all variants at the
disease locus are either deleterious or neutral, these like-
lihoods can be computed using a standard two-allele
model, with a hypothetical susceptibility allele A (cor-
responding to all deleterious alleles), with some fre-
quency p, and a normal allele a (corresponding to all
neutral alleles). The hypothesis can be modeledCp 1
by treating the variant as a genetic marker allele that
is in complete linkage disequilibrium, D, with the pro-
posed susceptibility allele A (i.e., ; ). Undervp 0 Dp 1
the hypothesis , the variant segregates indepen-Cp 0
dently of the disease, equivalent to the same model but
with and . Thus,vp 1/2 Dp 0
( )L VFP,V ,vp 0,Dp 1p
Bp ( )L VFP,V ,vp 1/2,Dp 0p
( ) ( )L P,VFvp 0,Dp 1 L P,VFvp 1/2,Dp 0p
p # .( ) ( )L P,VFvp 1/2,Dp 0 L P,VFvp 0,Dp 1p
If information is available from multiple families carry-
ing the same variant, then the overall evidence of cau-
sality is the product of the individual Bayes factors over
these (independent) families. When assessing the causali-
ty of a given variant over multiple families, we implicitly
assume that the variant under study is not in linkage
disequilibrium with a hidden deleterious mutation in
some but not all families being examined.
The ﬁrst of these likelihood ratios is similar to the
antilogarithm of the LOD score for linkage between the
variant and disease but with the additional information
arising from the fact that the variant is assumed to be
in phase with the susceptibility allele. The second ratio
is a correction for the fact that the proband is known
to carry the variant. These likelihoods can be calculated
using standard pedigree-analysis software. If there are
no other genes of interest (e.g., modiﬁer loci affecting
disease risk in carriers of the variant), then the likelihood
ratio can be computed straightforwardly in, for example,
Linkage (Lathrop et al. 1984). If necessary, likelihoods
based on more-complex models that also incorporate
other genes or known environmental risk factors can be
computed using, for example, the Pedigree Analysis
Package (Hasstedt 2002) or Mendel (Lange et al. 1988).
The formulation is essentially exact, providing that the
model (in particular, the penetrances) is correctly spec-
iﬁed. Thus, the complexity of the genetic model is limited
only by the software used for the analysis, with the only
restriction being that the software be capable of incor-
porating linkage disequilibrium. We have chosen to use
the Linkage package (Lathrop et al. 1984) for the anal-
yses described below. Sample Linkage parameter ﬁles
required in order to implement this approach are avail-
able from the authors on request.
The Bayes factor can also be used as a test of the
hypothesis of causality, by comparing B with its distri-
bution under the hypothesis of neutrality. This distri-
bution does not depend on the true penetrance param-
eters, and the test is therefore valid whether or not the
penetrances are correctly speciﬁed. The power of this
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Figure 1 Two sample pedigrees used to demonstrate calculation
of odds of causality (shown in table 1). Blackened symbols indicate
affected individuals; question marks (?) indicate phenotype changed
in table 1; plus () and minus () symbols indicate carrier status at
the sequence variant under assessment. Numbers are given for those
individuals speciﬁcally referred to in table 1.
Table 1
Bayes-Factor Comparison of the Two Approaches for Hypothetical
Data
Pedigree and Genotype
(Individual 302)/Phenotype
(Individuals 202 and 203)
Petersen
et al. (1998)
Full
Likelihood
Pedigree 1:
/Affected 5.33 (32.8a) 7.30 (7.37a)
/Unknown 5.33 5.28
/Unaffected 5.33 1.83
/Affected .38 .09
/Unknown .38 .38
/Unaffected .38 .88
Pedigree 2 .21 1.03
NOTE.—For details of the two approaches, see ﬁgure 1.
a Value obtained if one assumes that 202 and 203 are carriers of
the variant.
test will clearly depend on the accuracy of the penetrance
estimates. To illustrate the advantages of our implemen-
tation, consider the two pedigrees shown in ﬁgure 1.
The comparisons between the rare-allele method out-
lined by Petersen et al. (1998) and our proposed imple-
mentation are shown in table 1, assuming a genetic
model with allele frequency 0.001 and penetrances of
0.7 in carriers of the variant and 0.05 in noncarriers.
Several interesting features of the method can be seen.
First, it is reassuring that, when the two parents (202
and 203) are of unknown phenotype, the two methods
agree quite closely. Second, we note the rather broad
range of Bayes factors obtained using our proposed
method as a function of the phenotype of the untested
(but likely obligate carriers) parents. Note that if, in the
Petersen et al. (1998) rare-allele method, these are as-
sumed to be affected carriers, the evidence of causality
is heavily overstated (Bayes factor corresponding to odds
of 32.8:1 in favor of causality) because it does not prop-
erly take into account the dependence of the tested in-
dividuals. In our method, if these individuals were tested
positive, then the odds in favor of causality are only
slightly higher, 7.4:1. Last, the results for pedigree 2
show the effect of including untested individuals in the
analysis, with odds against causality of 5:1 if they are
not considered, compared with roughly even odds if the
two affected untested individuals are included. Some-
what surprisingly, untested unaffected individuals can
have an effect as well, if the assumed penetrance is high.
Thus, it is important that the pedigree information be
as complete as possible and that the distinction be made
between unaffected individuals and those of unknown
phenotype. In contrast to the method of Petersen et al.
(1998), the method described here uses all available
genotype information from the family, including any
unaffected individuals who have been tested. However,
since neither of the above pedigrees contains any tested
unaffected members, the difference in results is not due
to the inclusion of extra genotypes. In their article, Pe-
tersen et al. (1998) analyzed two published data sets; we
have reanalyzed one of them by using all the information
provided in the pedigrees (Barker et al. 1996) but as-
suming the same genetic model as Petersen et al. (1998).
For the two pedigrees carrying the R841W variant in
BRCA1, Bayes factors of 1.73 and 2.96 were obtained
by Petersen et al. (1998), using the exact method out-
lined in their article. Our reanalysis of these pedigrees,
including the tested unaffected individuals and untested
breast cancer cases, results in values of 0.66 and 0.89,
respectively. Combining the data from the two pedigrees,
Petersen et al. (1998) conclude that the hypothesis of
causality (under the speciﬁed penetrance model) is ﬁve
times more likely than noncausality; however, using all
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the data provided in the pedigrees, our analysis under
the same genetic model ﬁnds odds of 1.7:1 against cau-
sality from these data. If the unaffected individuals used
in our method but not the Petersen et al. (1998) ap-
proach are not considered in the analysis, application of
our method results in essentially even odds of causality
(Bayes factor of 1.06), compared with the 5:1 found by
Petersen et al. (1998). We also repeated the analysis us-
ing a model for inherited breast cancer (Easton et al.
1993) that takes into account both the ages at diagno-
sis of the affected individuals and the ages at last ob-
servation of the unaffected individuals (assumed to be
similar to their affected sisters). Under this perhaps-
more-realistic model, the odds are very slightly in favor
of causality (1.2:1). Note that this amino acid residue,
R841, shows considerable variation among the various
orthologues for which sequence data are available, with
two alternative amino acids present (neither of which
are the observed change, W) and no conservation other
than in chimpanzee (Orelli et al. 2001). This analysis,
as well as the illustrative examples shown in table 1,
point out the risks in using the simplistic approach of
Petersen et al. (1998), which in some circumstances
could result in spurious classiﬁcation of unknown se-
quence variants. In the case of unknown penetrance,
Petersen et al. (1998) used a Bayesian approach, inte-
grating over the prior distribution for the penetrance
(usually expressed as the risk ratio or hazard ratio be-
tween disease risk in carriers as compared with noncar-
riers). This approach could also easily be implemented
in the full-likelihood approach through the use of a shell
program, for example.
In summary, we have proposed a simple likelihood-
based framework and implementation, to provide more
informative and accurate assessment of causality for
DNA sequence variants of unknown functional signiﬁ-
cance. This information can then be used, in conjunction
with other lines of evidence, to assess the causality of
variants of uncertain clinical signiﬁcance.
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